Neurex Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurex Corporation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who wrote (388)	1/13/1998 10:53:00 PM
From: Dr. John M. de Castro	Read Replies (3) of 449

John, the patient population is one that is either refractory or non responsive to morphine. So the appropriate comparison is with placebo. This should be relatively easy for NXCO to meet this criteria given the data presented. > John McCarthy on Jan 13 1998 10:19PM EST > I assume if its (= to) or (better than) morphine - we win+ > otherwise , more testing. My major reservation is with the use of evaluable patients. DEPO got nailed by ODAC because they used evaluable patients for their comparison, while ODAC used intent to treat. There was a 15% drop out rate in the trial. So, the intent to treat data may not be as nice and clear cut as the data presented in the release. I also worry about side effects. The drug is a competitive NMDA antagonist. Such drugs have a history of producing psychological symptoms such as halucinations. The drug also has a history of problems with producing precipitous drops in blood pressure. Don't get me wrong, I'm impressed with the data. I am only putting out some cautions. This may not be the slam dunk that it appear on the surface. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next